A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19

Delphine C. Malherbe; Drishya Kurup; Christoph Wirblich; Adam J. Ronk; Chad Mire; Natalia Kuzmina; Noor Shaik; Sivakumar Periasamy; Matthew A. Hyde; Julie M. Williams; Pei-Yong Shi; Matthias J Schnell; Alexander Bukreyev.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-428442

Documentos relacionados

  1. Pharmacokinetics and Efficacy of Human Hyperimmune Intravenous Immunoglobulin Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Adult Syrian Hamsters.
  2. A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19.
  3. Absence of Vaccine-enhanced Disease With Unexpected Positive Protection Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model.
  4. Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2.
  5. The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection.
  6. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
  7. Phenotyping the virulence of SARS-CoV-2 variants in hamsters by digital pathology and machine learning.
  8. Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters.
  9. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
  10. Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea.